|Bid||170.83 x 100|
|Ask||174.90 x 100|
|Day's Range||170.77 - 173.90|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.23|
|Dividend & Yield||4.60 (2.67%)|
|1y Target Est||N/A|
Alder stock dove to a nearly three-year low Tuesday despite strong data in a Phase 3 migraine trial, making it competitive with Lilly, Amgen and Teva.
Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.